Bright Minds is a biotechnology company focused on drug development, specifically in approaches to neuroscience and mental health. They have developed selective 5-HT2A and 5-HT2C agonists for the treatment of conditions like epilepsy.

Bright Minds

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

COM:BRIGHTMINDSBIO

Bright Minds

Last Close

45.18

22/11 20:59

Market Cap

6.12M

Beta: -

Volume Today

2.35K

Avg: -

Analysis Not Available